Basal cell carcinomas (BCCs) are the most common nonmelanoma skin cancers. Dermoscopy is an indispensable tool to differentiate superficial BCC from other subtypes and between pigmented and not pigmented ones. Although surgery is considered the gold-standard therapy, new current pharmacological options are available and focus on tumor eradication, increasing cosmetic results and functionality. 5-fluorouracil (5-FU) is a cytostatic drug associated with antimetabolite effects and already approved as monotherapy for superficial BCCs treatment. A recent formulation combining of 5-FU 0.5% with salicylic acid 10% has been indicated for the management of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis of the face, forehead, and balding scalp in immunocompetent adult patients. This formulation has never been used as treatment for superficial BCC. In this article, we reported superficial BCC clinical and dermoscopic outcomes in two patients treated with this new topical agent, to assess its role in treating these lesions and to point out dermoscopy's usefulness in supporting clinical diagnosis and excluding tumor persistence or recurrence.

Diluvio, L., Lanna, C., Lozzi, F., Palumbo, V., Bianchi, L., Campione, E. (2019). Basal cell carcinomas treated with 0.5% 5-fluorouracil and 10% salicylic acid topical solution. DERMATOLOGIC THERAPY, e12908 [10.1111/dth.12908].

Basal cell carcinomas treated with 0.5% 5-fluorouracil and 10% salicylic acid topical solution

Bianchi, Luca;Campione, Elena
2019-04-09

Abstract

Basal cell carcinomas (BCCs) are the most common nonmelanoma skin cancers. Dermoscopy is an indispensable tool to differentiate superficial BCC from other subtypes and between pigmented and not pigmented ones. Although surgery is considered the gold-standard therapy, new current pharmacological options are available and focus on tumor eradication, increasing cosmetic results and functionality. 5-fluorouracil (5-FU) is a cytostatic drug associated with antimetabolite effects and already approved as monotherapy for superficial BCCs treatment. A recent formulation combining of 5-FU 0.5% with salicylic acid 10% has been indicated for the management of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis of the face, forehead, and balding scalp in immunocompetent adult patients. This formulation has never been used as treatment for superficial BCC. In this article, we reported superficial BCC clinical and dermoscopic outcomes in two patients treated with this new topical agent, to assess its role in treating these lesions and to point out dermoscopy's usefulness in supporting clinical diagnosis and excluding tumor persistence or recurrence.
9-apr-2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
5-fluorouracil; dermatoscopic features; dermoscopy; pigmented superficial basal cell carcinoma; salicylic acid; topical therapy
Diluvio, L., Lanna, C., Lozzi, F., Palumbo, V., Bianchi, L., Campione, E. (2019). Basal cell carcinomas treated with 0.5% 5-fluorouracil and 10% salicylic acid topical solution. DERMATOLOGIC THERAPY, e12908 [10.1111/dth.12908].
Diluvio, L; Lanna, C; Lozzi, F; Palumbo, V; Bianchi, L; Campione, E
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Basal cell carcinomas treated with 0.5% 5-fluorouracil and 10%salicylic acid topical solution.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 785.85 kB
Formato Adobe PDF
785.85 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/214268
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact